Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, shares his thoughts on long COVID-19 among those with type 2 diabetes and the rise of new-onset cases of type 1 diabetes throughout the pandemic.
Early data showing that type 2 diabetes may be a risk factor for long COVID-19 are very concerning, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association.
Transcript
Research shows type 2 diabetes may influence the likelihood of developing long COVID-19. What are your thoughts on this and have you seen it occur?
Long COVID-19 is really yet one more concerning aspect of the pandemic. We are seeing more and more cases. I certainly have had, in my practice, I see patients that continue to have a variety of constellation of symptoms. Sometimes that's hard to sort out, was that related to COVID-19 or people develop other conditions? And [the] temporal relationship often has people considering that that’s related to their COVID-19 infection. There is some early data suggesting that type 2 diabetes may be one of the risk factors for long COVID-19, and that’s very concerning.
Several studies have documented a rise in type 1 diabetes during the pandemic. What do you think accounts for this?
The American Diabetes Association funded a series of research grants as the pandemic was beginning, and a couple of those projects were looking at the ability of COVID-19 virus to infect beta cells. It may be that by direct attacking the beta cells, insulin-producing cells, that is leading to the development of type 1 diabetes, because there was a recent CDC report that followed other reports that have been out there of new cases of type 1 diabetes developing in children as a result of COVID-19 infection.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More